|
Acetylene tetrabromide |
CAS 79-27-6 | ||
CHBr2CHBr2 |
RTECS KI8225000 | ||
Synonyms & Trade Names Symmetrical tetrabromoethane; TBE; Tetrabromoacetylene; Tetrabromoethane; 1,1,2,2-Tetrabromoethane |
DOT ID & Guide 2504 159 |
Exposure
|
NIOSH REL: See Appendix D | ||
OSHA PEL: TWA 1 ppm (14 mg/m3) | |||
IDLH 8 ppm See: 79276 | Conversion 1 ppm = 14.14 mg/m3 |
Physical Description Pale-yellow liquid with a pungent odor similar to camphor or iodoform. [Note: A solid below 32°F.] |
|||
MW: 345.7 |
BP: 474°F (Decomposes) |
FRZ: 32°F |
Sol: 0.07% |
VP: 0.02 mmHg |
IP: ? |
|
Sp.Gr: 2.97 |
Fl.P: NA |
UEL: NA |
LEL: NA |
|
Noncombustible Liquid | |||
Incompatibilities & Reactivities Strong caustics; hot iron; reducing metals such as aluminum, magnesium & zinc |
Measurement Methods NIOSH 2003 See: NMAM or OSHA Methods |
Personal Protection & Sanitation (See protection) Skin: Prevent skin contact Eyes: Prevent eye contact Wash skin: When contaminated Remove: When wet or contaminated Change: No recommendation |
First Aid (See procedures) Eye: Irrigate immediately Skin: Water flush promptly Breathing: Respiratory support Swallow: Medical attention immediately |
Important additional information about respirator selection Respirator Recommendations OSHA Up to 8 ppm: (APF = 10) Any supplied-air respirator (APF = 50) Any self-contained breathing apparatus with a full facepiece Emergency or planned entry into unknown concentrations or IDLH conditions: (APF = 10,000) Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode (APF = 10,000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained positive-pressure breathing apparatus Escape: (APF = 50) Any air-purifying, full-facepiece respirator (gas mask) with a chin-style, front- or back-mounted organic vapor canister/Any appropriate escape-type, self-contained breathing apparatus |
|
Exposure Routes inhalation, ingestion, skin and/or eye contact | |
Symptoms Irritation eyes, nose; anorexia, nausea; headache; abdominal pain; jaundice; leukocytosis (increased blood leukocytes); central nervous system depression | |
Target Organs
Eyes, respiratory system, liver, central nervous system |
See also: INTRODUCTION See ICSC CARD: 1235 See MEDICAL TESTS: 0005 |